Clinical Trial Update: Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of ruxolitinib and enasidenib in patients with accelerated- or blast-phase myeloproliferative neoplasms or chronic-ph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myeloproliferative Neoplasms

Drugs mentioned

• Enasidenib (enasidenib)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: John Mascarenhas | Conditions: Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis | Phase 2 | Status: COMPLETED | Results posted: 2024-12-18